SPEC Stock Overview
SpectraCure AB (publ) engages in the development of cancer treatment system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SpectraCure AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.69 |
| 52 Week High | kr6.60 |
| 52 Week Low | kr2.00 |
| Beta | 0.71 |
| 1 Month Change | -2.18% |
| 3 Month Change | -22.48% |
| 1 Year Change | -53.62% |
| 3 Year Change | -69.55% |
| 5 Year Change | -83.00% |
| Change since IPO | 45.41% |
Recent News & Updates
We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely
Feb 23
We're Not Very Worried About SpectraCure's (STO:SPEC) Cash Burn Rate
Nov 09Recent updates
We're Hopeful That SpectraCure (STO:SPEC) Will Use Its Cash Wisely
Feb 23We're Not Very Worried About SpectraCure's (STO:SPEC) Cash Burn Rate
Nov 09Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth
Jul 27Companies Like SpectraCure (STO:SPEC) Are In A Position To Invest In Growth
Mar 09SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans
Nov 08SpectraCure (STO:SPEC) Is In A Good Position To Deliver On Growth Plans
Jul 26We Think SpectraCure (STO:SPEC) Can Afford To Drive Business Growth
Mar 19Here's Why We're Not Too Worried About SpectraCure's (STO:SPEC) Cash Burn Situation
Nov 16We Think SpectraCure (STO:SPEC) Can Easily Afford To Drive Business Growth
Aug 03We're Not Worried About SpectraCure's (STO:SPEC) Cash Burn
Apr 16Companies Like SpectraCure (STO:SPEC) Can Afford To Invest In Growth
Jan 01Shareholder Returns
| SPEC | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 4.5% | 2.3% | 0.1% |
| 1Y | -53.6% | -5.4% | 11.2% |
Return vs Industry: SPEC underperformed the Swedish Medical Equipment industry which returned -6.7% over the past year.
Return vs Market: SPEC underperformed the Swedish Market which returned 9.4% over the past year.
Price Volatility
| SPEC volatility | |
|---|---|
| SPEC Average Weekly Movement | 12.8% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: SPEC's share price has been volatile over the past 3 months.
Volatility Over Time: SPEC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 16 | Masoud Khayyami | www.spectracure.com |
SpectraCure AB (publ) engages in the development of cancer treatment system. It develops Q-PRO, a laser device; and IDOSE software with interstitial photodynamic therapy system for the treatment of prostate cancer. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (publ) Fundamentals Summary
| SPEC fundamental statistics | |
|---|---|
| Market cap | kr261.28m |
| Earnings (TTM) | -kr20.44m |
| Revenue (TTM) | kr318.00k |
821.6x
P/S Ratio-12.8x
P/E RatioIs SPEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEC income statement (TTM) | |
|---|---|
| Revenue | kr318.00k |
| Cost of Revenue | -kr9.54m |
| Gross Profit | kr9.86m |
| Other Expenses | kr30.30m |
| Earnings | -kr20.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 3,100.31% |
| Net Profit Margin | -6,427.99% |
| Debt/Equity Ratio | 0% |
How did SPEC perform over the long term?
See historical performance and comparison